Filtered By:
Drug: Activase
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 1186 results found since Jan 2013.
Fatal Multiple Systemic Emboli after Intravenous Thrombolysis for Cardioembolic Stroke
Our objective is to present a case of fatal multiple systemic emboli after intravenous thrombolysis for cardioembolic stroke. A 64-year-old woman with atrial fibrillation was admitted for evaluation of sudden consciousness disturbance, right hemiplegia, and aphasia. Diffusion-weighted imaging showed no early ischemic changes of the brain, and magnetic resonance angiography (MRA) showed occlusion of the left middle cerebral artery (MCA). One hour after initiation of 0.6 mg/kg of intravenous alteplase, the MCA was partially recanalized. Her symptoms disappeared the following day. We began intravenous heparin for secondary pr...
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Koji Tanaka, Tomoyuki Ohara, Akiko Ishigami, Yoshihiko Ikeda, Toshinori Matsushige, Tetsu Satow, Hatsue Ishibashi-Ueda, Koji Iihara, Kazunori Toyoda Tags: Case Reports Source Type: research
"Heparin-Less" Protocol for Endovascular Treatment of Acute Ischemic Stroke (P4.209)
Conclusions: We observed "heparin less" endovascular treatment results in high rates of recanalization with an acceptable rate of post thrombolytic ICH.Disclosure: Dr. Khan has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Khan, A., Hassan, A., Zafar, T., Malik, A., Adil, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research
Interim Recanalization in Acute Ischemic Stroke Patients Selected for Endovascular Treatment by CT Angiography (P4.210)
Conclusions:A relatively high proportion of patients have interim recanalization between CT angiogram and cerebral angiogram in acute ischemic stroke patients selected for endovascular treatment.Disclosure: Dr. Qureshi has nothing to disclose. Dr. Siddiq has nothing to disclose. Dr. Kainth has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Qureshi, M., Siddiq, F., Kainth, D., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research
Thromboelastographic Changes in Patients Experiencing an Acute Ischemic Stroke and Receiving Alteplase
Conclusions: Our study suggests that thromboelastogram (TEG) is a useful tool for determining changes in the coagulation system of patients whom have received recombinant tissue plasminogen activator (rt-PA). Further study is needed to determine if TEG can be used to predict those patients who may be at higher risk of adverse events because of rt-PA.
Source: Journal of Stroke and Cerebrovascular Diseases - January 21, 2014 Category: Neurology Authors: A. Shaun Rowe, Christal L. Greene, Carolyn C. Snider, Roger C. Carroll, Brian F. Wiseman, Jennifer M. Henry, J. Russell Langdon, Robert M. Craft Tags: Original Articles Source Type: research
Predicting Stroke Outcome Using Clinical- versus Imaging-based Scoring System
Several models to predict outcome in ischemic stroke patients receiving intravenous (i.v.) alteplase can be divided into clinical-based and imaging-based systems. Alberta Stroke Program Early Computed Tomography (CT) Score (ASPECTS) and Dense cerebral artery sign/early infarct signs on admission CT scan, prestroke modified Rankin Scale (mRS) score, Age, Glucose level at baseline, Onset-to-treatment time, and baseline National Institutes of Health Stroke Scale score (DRAGON) are typical imaging- and clinical-based scoring systems, respectively.
Source: Journal of Stroke and Cerebrovascular Diseases - January 6, 2015 Category: Neurology Authors: Joon Hyun Baek, Kitae Kim, Yeong-Bae Lee, Kee-Hyung Park, Hyeon-Mi Park, Dong-Jin Shin, Young Hee Sung, Dong Hoon Shin, Oh Young Bang Source Type: research
Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
ConclusionsWe have developed a predetermined statistical analysis plan for the ENhanced Control of Hypertension And Thrombolysis strokE stuDy alteplase dose arm which is to be followed to avoid analysis bias arising from prior knowledge of the study findings.
Source: International Journal of Stroke - August 18, 2015 Category: Neurology Authors: Craig S. Anderson, Mark Woodward, Hisatomi Arima, Xiaoying Chen, Richard I. Lindley, Xia Wang, John Chalmers, Tags: Protocol Source Type: research
Statistical analysis plan for evaluating low ‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
ConclusionsWe have developed a predetermined statistical analysis plan for the ENhanced Control of Hypertension And Thrombolysis strokE stuDy alteplase dose arm which is to be followed to avoid analysis bias arising from prior knowledge of the study findings.
Source: International Journal of Stroke - August 17, 2015 Category: Neurology Authors: Craig S. Anderson, Mark Woodward, Hisatomi Arima, Xiaoying Chen, Richard I. Lindley, Xia Wang, John Chalmers, Tags: Protocol Source Type: research
Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5)
Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset. We aimed to evaluate current edaravone treatment practices and the efficacy and safety of edaravone used with recombinant tissue plasminogen activator (tPA) in AIS patients within 4.5 hours of onset. The results were compared with those of the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Registry (SITS-ISTR) study.
Source: Journal of Stroke and Cerebrovascular Diseases - November 21, 2016 Category: Neurology Authors: Takenori Yamaguchi, Hideto Awano, Hiroaki Matsuda, Norio Tanahashi, PROTECT4.5 Investigators Source Type: research
Drip 'n Ship Versus Mothership for Endovascular Treatment Brief Report
Conclusions—Drip ‘n Ship demonstrates that a PSC that is in close proximity to a CSC remains significant only when the PSC is able to achieve a door-to-needle time of ≤30 minutes when the CSC is also efficient.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Matthew S.W. Milne, Jessalyn K. Holodinsky, Michael D. Hill, Anders Nygren, Chao Qiu, Mayank Goyal, Noreen Kamal Tags: Quality and Outcomes, Ischemic Stroke Brief Reports Source Type: research
Cost of Alteplase Has More Than Doubled Over the Past Decade Brief Report
Conclusions—We found a striking increase in the cost of alteplase over the last decade, with a 100 mg vial now with a CMS payment of ≈$6400, a>100% increase over 10 years. During the same time frame, the DRG base payment to hospitals increased by only 8%, and alteplase cost increased from 27% of the payment in 2006 to 53% in 2013. Researchers and stroke physicians should be aware of these changes in drug costs and their impact on cost-effectiveness analyses.
Source: Stroke - June 26, 2017 Category: Neurology Authors: Dawn Kleindorfer, Joseph Broderick, Bart Demaerschalk, Jeffrey Saver Tags: Cost-Effectiveness, Ischemic Stroke Brief Reports Source Type: research
Influence of Penumbral Reperfusion on Clinical Outcome Depends on Baseline Ischemic Core Volume Clinical Sciences
This study included 1507 patients. Reperfused penumbral volume had moderate ability to predict 90-day mRS 0 to 1 (area under the curve, 0.77; R2, 0.28; P
Source: Stroke - September 25, 2017 Category: Neurology Authors: Chushuang Chen, Mark W. Parsons, Matthew Clapham, Christopher Oldmeadow, Christopher R. Levi, Longting Lin, Xin Cheng, Min Lou, Timothy J. Kleinig, Kenneth S. Butcher, Qiang Dong, Andrew Bivard Tags: Ischemic Stroke Original Contributions Source Type: research
Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy
Thrombolytic treatment (recombinant tissue plasminogen activator [rt-PA]) has established efficacy in acute ischemic stroke, but pregnancy has been an exclusion criterion for all clinical trials that validated alteplase in acute stroke, so our knowledge about its use in this condition is limited.Herein we report the successful use of intravenous rt-PA thrombolysis, uncomplicated by neither hemorrhage development nor other complication in a woman who was 13 weeks pregnant with acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: Anne Landais, Hugo Chaumont, Rachel Dellis Tags: Case Studies Source Type: research
Letter by Niu et al Regarding Article, “Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis” Letter to the Editor
Source: Stroke - May 25, 2018 Category: Neurology Authors: Peng-Peng Niu, Bo Song, Yu-Ming Xu Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Letters to the Editor Source Type: research
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.
Source: Journal of Stroke and Cerebrovascular Diseases - October 13, 2018 Category: Neurology Authors: Victoria A. Chang, Dawn M. Meyer, Brett C. Meyer Source Type: research
Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review
Background and Aim: The current American Heart Association guidelines for the management of acute ischemic stroke advise against the use of intravenous (IV) alteplase in patients with recurrent stroke occurring within 90 days of their index event. Following these guidelines strictly, patients having early recurrent ischemic stroke would be unable to avail of this reperfusion strategy that has been proven to confer superior clinical outcomes. While some registry-based studies have demonstrated the safety of IV alteplase in this subgroup of patients, data on the repeated use of the drug are lacking.
Source: Journal of Stroke and Cerebrovascular Diseases - July 28, 2019 Category: Neurology Authors: Robert Joseph Cruz Sarmiento, Jose Danilo Bengzon Diestro, Adrian Isidoro Espiritu, Maria Cristina Zarsadias San Jose Source Type: research
